Novartis, the Swiss pharmaceutical giant, reached a confidential settlement with the estate of Henrietta Lacks in late February 2026, resolving a lawsuit that accused the company of profiting from cells taken from Lacks without her consent more than seven decades ago. The settlement, finalized in federal court in Baltimore, Maryland, marks the second time a major biopharma company has resolved claims brought by the Lacks family over the commercial exploitation of the HeLa cell line — one of the most consequential biological materials in modern medical history. Financial terms were not disclosed, but the case itself has forced a long-overdue reckoning within the pharmaceutical industry over who profits when human tissue is taken without permission.
The Lacks estate filed the lawsuit against Novartis in 2024, seeking the full amount of net profits the company obtained by commercializing the HeLa cell line. The complaint specifically named products like Famvir, a herpes treatment, Kymriah, a CAR-T cancer therapy, and Zolgensma, a gene therapy — all allegedly developed using cells the family says were stolen. In a joint statement, both parties said they were “pleased they were able to find a way to resolve this matter filed by Henrietta Lacks’ Estate outside of court” but declined further comment. This article examines what the settlement means, the history behind the HeLa cells, the broader legal campaign by the Lacks estate, and what still lies ahead.
Table of Contents
- What Did the Novartis Settlement With the Henrietta Lacks Family Actually Resolve?
- The History of HeLa Cells and Why Consent Matters Decades Later
- The Broader Legal Campaign Against Pharma Companies
- What Products Were Allegedly Developed Using HeLa Cells?
- Limitations of the Legal Strategy and Unresolved Questions
- The Role of Race and Medical Ethics in the Lacks Legacy
- What Comes Next for the Lacks Estate and Pharmaceutical Accountability
- Conclusion
- Frequently Asked Questions
What Did the Novartis Settlement With the Henrietta Lacks Family Actually Resolve?
The settlement resolved a federal lawsuit alleging that Novartis unjustly enriched itself by using the HeLa cell line — derived from tissue samples taken from Henrietta Lacks during cancer treatment in 1951 — to develop and commercialize pharmaceutical products. The estate’s legal theory was straightforward: Lacks never consented to her cells being used for research or profit, and companies that built billion-dollar therapies on the back of that tissue owe the family compensation. Novartis is not a small player here. Kymriah alone was approved by the FDA in 2017 as a groundbreaking cancer treatment, and Zolgensma, used to treat spinal muscular atrophy, carries a list price that has made it one of the most expensive drugs in the world. What the settlement did not resolve is the broader question of how much these companies actually owe. Because the terms are confidential, there is no public benchmark for what the Lacks estate received.
That matters because it leaves future defendants — and there are more — without a clear sense of what settling might cost. It also means the public cannot evaluate whether the compensation was proportional to the profits generated. For a case that has become a symbol of medical exploitation and racial injustice, the secrecy is notable, even if it is standard practice in litigation of this kind. The confidential nature of both the Novartis and the earlier Thermo Fisher settlement raises a legitimate concern: without transparency, these agreements risk becoming quiet payoffs that let corporations avoid public accountability. The Lacks family may be satisfied with the outcome, and that is their right. But the systemic issues the case represents — consent, exploitation, the commodification of human biology — are not fully addressed by private deals.
The History of HeLa Cells and Why Consent Matters Decades Later
Henrietta Lacks was a Black woman from Baltimore who sought treatment for cervical cancer at Johns Hopkins Hospital in 1951. During her treatment, doctors removed tissue samples without her knowledge or consent — a practice that was not unusual at the time but is now widely regarded as a profound ethical violation. Lacks died later that year at age 31. Her cells, however, did not. Researchers discovered that her tissue had a remarkable property: the cells continued to divide and grow indefinitely in laboratory conditions. They became the first “immortal” human cell line, and scientists named them HeLa. The impact of HeLa cells on medical science is difficult to overstate. They have been used in research that led to genetic mapping, the development of polio vaccines, advances in cancer treatment, and most recently, COVID-19 vaccines.
Tens of thousands of scientific papers reference HeLa cells. Companies have bought, sold, and built products around them for decades. However, if you assume that existing consent laws would have prevented this from happening today, think again. Modern informed consent regulations are significantly stronger than what existed in 1951, but disputes over tissue ownership and the commercial use of biological materials remain legally murky. The Lacks case is extreme, but it is not entirely unique — it just happens to involve the most famous cell line in history. The Lacks family learned about the existence and widespread use of HeLa cells only in the 1970s, more than two decades after Henrietta’s death. They were never compensated, never consulted, and for years had no legal avenue to challenge what had happened. The family’s attorney, Ben Crump, has framed the lawsuits as addressing a racist medical system that routinely exploited Black patients — a characterization that is well-supported by historical evidence, from the Tuskegee syphilis study to J. Marion Sims’ experiments on enslaved women.
The Broader Legal Campaign Against Pharma Companies
Novartis is the second biopharma company to settle with the Lacks estate, following Thermo Fisher Scientific, which resolved an “unjust enrichment” lawsuit in 2023. That settlement also involved undisclosed financial terms. The pattern is clear: the Lacks estate, represented by Crump and his legal team, is systematically pursuing companies that profited from HeLa cells. The legal theory — that these companies were unjustly enriched by commercializing biological material taken without consent — has proven effective enough to produce settlements without going to trial. Active litigation remains against at least two other companies.
Ultragenyx Pharmaceutical faces a lawsuit filed in Baltimore federal court, and Viatris is also a defendant in pending claims. These cases will test whether the legal strategy continues to produce results or whether a company eventually decides to fight the claims at trial. Each defendant faces a difficult calculus: the public relations cost of arguing in open court that a company has the right to profit from a Black woman’s stolen cells is enormous, regardless of the legal merits. The fact that these cases are being filed and settled in Baltimore is significant. It is the city where Lacks lived and died, where Johns Hopkins is located, and where juries would likely be sympathetic to the family’s claims. Venue matters in litigation, and the Lacks estate has chosen its battlefield carefully.
What Products Were Allegedly Developed Using HeLa Cells?
The Lacks estate’s complaint against Novartis specifically identified three products: Famvir, an antiviral drug used to treat herpes; Kymriah, a CAR-T cell therapy approved for certain types of leukemia and lymphoma; and Zolgensma, a gene therapy for spinal muscular atrophy. These are not obscure medications. Kymriah was one of the first CAR-T therapies approved by the FDA and represented a genuine breakthrough in cancer treatment. Zolgensma, priced at over two million dollars per treatment at launch, was one of the most expensive drugs ever brought to market. The tradeoff at the heart of this case is uncomfortable. HeLa cells genuinely contributed to medical advances that have saved and improved millions of lives.
The science is real, and the benefits to humanity are measurable. But that progress was built on an act of exploitation — tissue taken from a dying woman without her knowledge, then commercialized for decades while her family lived in poverty and many could not afford health insurance. Acknowledging both realities simultaneously is necessary. The scientific value of HeLa cells does not justify how they were obtained, and the injustice of their origin does not diminish their contribution to medicine. It is also worth noting that the specific role HeLa cells played in the development of each product varies. Some drugs may have relied on HeLa cells primarily during early-stage research, while others may have used them more extensively throughout development and testing. The legal question of how directly HeLa cells contributed to a product’s commercial success — and therefore how much profit is attributable to them — is complex and fact-specific.
Limitations of the Legal Strategy and Unresolved Questions
One significant limitation of the Lacks estate’s legal approach is that confidential settlements, by definition, do not create legal precedent. No court has ruled on the merits of the family’s claims. No judge has issued an opinion establishing that pharmaceutical companies owe compensation for using HeLa cells. If a future defendant refuses to settle, the estate would need to prove its case at trial — something that has not yet happened. The legal theory of unjust enrichment is viable, but it has not been tested in a courtroom in this specific context. There is also the question of scope. HeLa cells have been used by thousands of researchers and hundreds of companies over more than seven decades.
The Lacks estate cannot realistically sue every entity that has ever used the cell line. The family appears to be targeting the largest and most prominent pharmaceutical companies — those with the deepest pockets and the most to lose reputationally. That is a practical litigation strategy, but it means that most of the commercial value extracted from HeLa cells will never be accounted for. A further complication is that the law governing the ownership of human tissue and cells is a patchwork. The landmark 1990 California Supreme Court case Moore v. Regents of the University of California held that a patient does not have property rights over cells removed during medical procedures. While the Lacks case involves different facts and a different jurisdiction, the legal landscape around biological material ownership remains unsettled, and defendants in future cases may lean on this precedent.
The Role of Race and Medical Ethics in the Lacks Legacy
Ben Crump’s framing of the Lacks lawsuits as a racial justice issue is not rhetorical excess. The history of American medicine is littered with examples of Black patients being used as research subjects without consent. Henrietta Lacks’ story sits squarely within that tradition. She was a Black woman treated at a segregated ward of Johns Hopkins Hospital, and the doctors who took her cells did so in a medical system that routinely treated Black bodies as resources rather than patients.
The fact that her cells generated incalculable scientific and commercial value while her descendants struggled financially adds a layer of economic injustice to the ethical violation. Rebecca Skloot’s 2010 book, “The Immortal Life of Henrietta Lacks,” brought the story to mainstream attention and forced institutions to grapple with the ethical implications. Johns Hopkins, while not a defendant in the current lawsuits, has acknowledged the historical wrong and named a building after Lacks. But acknowledgment is not compensation, and the lawsuits are testing whether the pharmaceutical industry will be held financially accountable for profiting from this particular injustice.
What Comes Next for the Lacks Estate and Pharmaceutical Accountability
The resolution of the Novartis case does not end the Lacks estate’s legal campaign. With active lawsuits against Ultragenyx Pharmaceutical and Viatris still pending, the family’s attorneys will continue pressing claims against companies that commercially exploited HeLa cells. The outcomes of those cases — whether they settle or go to trial — will shape whether the pharmaceutical industry faces any lasting structural accountability or whether the Lacks settlements remain isolated events.
Looking forward, the Lacks cases may also influence how the industry handles consent and compensation for biological materials going forward. Several states have strengthened genetic privacy laws in recent years, and the Lacks litigation has kept public attention on the gap between ethical norms and legal requirements. Whether that attention translates into meaningful regulatory change remains an open question, but the Lacks family has already accomplished something significant: they have made it commercially and reputationally costly for pharmaceutical companies to ignore the origins of one of science’s most important tools.
Conclusion
The Novartis settlement with the Henrietta Lacks estate is both a milestone and an incomplete resolution. It is the second confidential agreement between a major pharmaceutical company and the family of a woman whose cells were taken without consent and used to generate enormous scientific and commercial value. The settlement validates the family’s legal strategy and signals to other defendants that fighting these claims in court carries significant risk. At the same time, the confidential nature of the terms means the public cannot assess whether the compensation is proportional to the profits generated — or whether these agreements represent genuine accountability or just the cost of avoiding bad press.
What remains clear is that the story of Henrietta Lacks is no longer just a cautionary tale about medical ethics. It is an active legal and financial reckoning. The Lacks estate has pending lawsuits against Ultragenyx and Viatris, and the outcomes of those cases will determine whether the pharmaceutical industry’s use of HeLa cells results in meaningful consequences. For consumers, patients, and anyone who has benefited from the medical advances enabled by HeLa cells — which is essentially everyone — these cases are a reminder that scientific progress and justice are not the same thing, and that the debts of the past do not expire just because the science moved on.
Frequently Asked Questions
Who was Henrietta Lacks?
Henrietta Lacks was a Black woman from Baltimore who was treated for cervical cancer at Johns Hopkins Hospital in 1951. During her treatment, doctors removed tissue samples without her knowledge or consent. Those cells became the HeLa cell line, the first immortal human cell line, and have been used in medical research for over seven decades.
What did Novartis settle for?
The financial terms of the Novartis settlement are confidential. Both Novartis and the Lacks estate issued a joint statement saying they were pleased to resolve the matter outside of court but declined to disclose the amount. The earlier Thermo Fisher settlement was also undisclosed.
Which companies has the Lacks estate sued?
The Lacks estate has pursued lawsuits against multiple pharmaceutical companies. Thermo Fisher Scientific settled in 2023, Novartis settled in February 2026, and active litigation remains against Ultragenyx Pharmaceutical and Viatris. All cases were filed in Baltimore federal court.
What products did Novartis allegedly develop using HeLa cells?
The Lacks estate’s lawsuit identified three Novartis products: Famvir (a herpes antiviral drug), Kymriah (a CAR-T cancer therapy), and Zolgensma (a gene therapy for spinal muscular atrophy).
Why are HeLa cells so important to medical science?
HeLa cells were the first human cells that could survive and replicate indefinitely in a laboratory setting. They have been used in research leading to genetic mapping, polio vaccines, cancer treatments, and COVID-19 vaccines, among thousands of other scientific advances.
Can the Lacks family sue every company that has used HeLa cells?
In theory, the unjust enrichment claims could apply broadly, but practically, the estate is targeting the largest pharmaceutical companies that commercially developed products using HeLa cells. Suing every researcher or institution that has used the cell line would be logistically impossible.